



• **Name:** Jun Ho Jang

• **Current Position:** Professor,
Division of Hematology-Oncology
School of Medicine, Samsung Medical Center,
SungKyunKwan University, Seoul, Korea

• **Country:** Korea

• **Educational Background:**

1986-1992 Yonsei University College of Medicine, Seoul, Korea
1992 M.D. No.46514, Korea
1998-2000 Master Degree, Graduate School, Yonsei University, Seoul, Korea
2000 Korean Board of Internal Medicine No.6448
2000-2002 Ph.D Degree, Graduate School, Yonsei University, Seoul, Korea
2002-2004 Post-Doctoral fellowship, University of Michigan, Ann Arbor, USA

• **Professional Experience:**

1995-1996 Internship
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
1996-2000 Residency, Internal Medicine
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2000-2002 Fellowship, Hematology-Oncology
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2002-2004 Post-Doctoral Research fellowship
University of Michigan, Ann Arbor, Michigan, USA
2004-2007 Assistant professor,
Department of Hematology-Oncology, Ajou University School of
Medicine, Suwon, Korea
2007-2013 Associate Professor
Division of Hematology-Oncology, School of Medicine
SungKyunKwan University, Samsung Medical Center, Seoul, Korea
2014- Professor
Division of Hematology-Oncology, School of Medicine
SungKyunKwan University, Samsung Medical Center, Seoul, Korea



• Professional Organizations:

- The Korean Society of Hematology
- The Korean Society of Hematopoietic Stem Cell Transplantation
- The American Society of Hematology
- The European Hematology Association

• Main Scientific Publications:

1. Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, Kim JA, Oh IH, **Jang JH**. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. *Lancet Haematol*. 2019 Nov;6(11):e562-e572. (Corresponding author)
2. Jung KS, Kim YJ, Kim YK, Park SK, Kim HG, Kim SJ, Park J, Choi CW, Do YR, Kim I, Park S, Mun YC, Jeong SH, Kim MK, Yi HG, Chang MH, Kim SY, Lee JH, Jang JH. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. *Clin Lymphoma Myeloma Leuk*. 2019 Oct;19(10):656-664. (Corresponding author)
3. Park S, Choi EK, Kim IR, Cho J, Jang JH. Comparison of quality of life and depression between hematopoietic stem cell transplantation survivors and their spouse caregivers. *Blood Res*. 2019 Jun;54(2):137-143. (Corresponding author)
4. Sakurai M, Jang JH, Chou WC, Kim JS, Wilson A, Nishimura JI, Chiou TJ, Kanakura Y, Lee JW, Okamoto S. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. *Int J Hematol*. 2019 Oct;110(4):411-418. (Co-First Author)
5. Kim JS, Cheong JW, Mun YC, Jang JH, Jo DY, Lee JW; Aplastic Anemia Working Party of the Korean Society of **Hematology**. Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. *Ann Hematol*. 2019 Oct;98(10):2273-2281. (Co-Author)
6. Abdullah HR, Ang AL, Froessler B, Hofmann A, Jang JH, Kim YW, Lasocki S, Lee JJ, Lee SY, Lim KKC, Singh G, Spahn DR, Um TH; Asia-Pacific PBM Expert Consensus Meeting Working Group. Getting patient blood management Pillar 1 right in the Asia-Pacific: a call for action. *Singapore Med J*. 2019 May 2. doi: 10.11622/smedj.2019037. [Epub ahead of print] (Co-First Author)
7. Frey N, Jang JH, Szer J, Illés Á, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. *Lancet Haematol*. 2019 Mar;6(3):e122-e131. (Co-First Author)
8. Yi JH, Park S, Kim JH, Won YW, Lim DH, Han B, Uhm J, Kim HS, Jung CW, Jang JH. A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine. *Oncotarget*. 2018 Jan 2;9(5):6607-6614. (Corresponding author)

9. Yoo KH, Kang D, Kim IR, Choi EK, Kim JS, Yoon SS, Lee CH, Park S, Kim SJ, Kim K, Kim WS, Jung CW, Choi HJ, Jang JH, Cho J. Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. *Bone Marrow Transplant.* 2018 Aug;53(8):967-976. (Corresponding author)
10. **Jang JH**, Kim JY, Mun YC et al. Management of immune thrombocytopenia: Korean experts recommendation in 2017. *Blood Res.* 2017 Dec;52(4):254-263 (First Author)
11. Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, **Jang JH**, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. *BMC Cancer.* 2017 Dec 14;17(1):852 (Co-Author)
12. **Jang JH**, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK, Lee JW. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. *J Korean Med Sci.* 2016 Feb;31(2):214-21 (First Author)
13. Kim JS, **Jang JH**, Yoon SS, Lee JH, Kim YK, Jo DY, Chung JS, Sohn SK, Lee JW. Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. *Ann Hematol.* 2016 Jan;95(1):125-33. (Co-Author)
14. Park S, Yoon SS, Lee JH, Park JS, **Jang JH**, Lee JW. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia. *Int J Hematol.* 2015 Oct 28. (Corresponding Author)
15. Platzbecker , Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, **Jang JH**, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. *Lancet Haematol.* 2015 Oct;2(10):e417-26 (Co-Author)
16. Jeong SH, Kim YJ, Lee JH, Kim YK, Kim SJ, Park SK, Do YR, Kim I, Mun YC, Kim HG, Lee WS, Yi HG, Joo YD, Choi CW, Kim SR, Na SM, **Jang JH**. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. *Oncotarget.* 2015. Oct 26 (Corresponding Author)
17. Park S, Jung CW, Kim K, Kim SJ, Kim WS, **Jang JH**. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. *Oncotarget.* 2015. Oct. 26 (Corresponding Author)
18. Jung HA, Maeng CH, Kim M, Kim S, Jung CW, **Jang JH**. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. *Oncotarget.* 2015 vol6, No.18: 16653-62 (Corresponding Author)
19. **Jang JH**, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. *Int J Hematol.* 2015 (First Author)